Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates
Dapeng Li, Robert J. Edwards, Kartik Manne, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer, Frances Ayres, Tandile Hermanus, et al.
Nature Medicine (2021) Vol. 27, Iss. 4, pp. 622-625
Open Access | Times Cited: 1233
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity
S. Gobeil, Katarzyna Janowska, Shana McDowell, et al.
Science (2021) Vol. 373, Iss. 6555
Open Access | Times Cited: 395
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
Xiaoying Shen, Haili Tang, Charlene McDanal, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 4, pp. 529-539.e3
Open Access | Times Cited: 377
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Qianqian Zhang, Rong Xiang, Shanshan Huo, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 300
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer, Frances Ayres, Tandile Hermanus, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 283
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
Kevin O. Saunders, Esther Lee, Robert Parks, et al.
Nature (2021) Vol. 594, Iss. 7864, pp. 553-559
Open Access | Times Cited: 235
Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
Irfan Ullah, Jérémie Prévost, Mark S. Ladinsky, et al.
Immunity (2021) Vol. 54, Iss. 9, pp. 2143-2158.e15
Open Access | Times Cited: 193
Structure of SARS-CoV-2 spike protein
Jun Zhang, Tianshu Xiao, Yongfei Cai, et al.
Current Opinion in Virology (2021) Vol. 50, pp. 173-182
Open Access | Times Cited: 190
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
David R. Martinez, Alexandra Schäfer, Sarah R. Leist, et al.
Science (2021) Vol. 373, Iss. 6558, pp. 991-998
Open Access | Times Cited: 177
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
Rachel Yamin, Andrew Jones, Hans-Heinrich Hoffmann, et al.
Nature (2021) Vol. 599, Iss. 7885, pp. 465-470
Open Access | Times Cited: 162
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
Michael Joyce, Wei‐Hung Chen, Rajeshwer S. Sankhala, et al.
Cell Reports (2021) Vol. 37, Iss. 12, pp. 110143-110143
Open Access | Times Cited: 149
Current status of therapeutic monoclonal antibodies against SARS-CoV-2
Sanjeev Kumar, Anmol Chandele, Amit Sharma
PLoS Pathogens (2021) Vol. 17, Iss. 9, pp. e1009885-e1009885
Open Access | Times Cited: 97
A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
Laura A. VanBlargan, Lucas J. Adams, Zhuoming Liu, et al.
Immunity (2021) Vol. 54, Iss. 10, pp. 2399-2416.e6
Open Access | Times Cited: 94
Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 78
Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
Harini Natarajan, Andrew R. Crowley, Savannah E. Butler, et al.
mBio (2021) Vol. 12, Iss. 2
Open Access | Times Cited: 72
Distinctive features of severe SARS-CoV-2 pneumonia
G. R. Scott Budinger, Alexander V. Misharin, Karen M. Ridge, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 14
Open Access | Times Cited: 69
Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
Gabriele Cerutti, Yicheng Guo, Pengfei Wang, et al.
Cell Reports (2021) Vol. 37, Iss. 5, pp. 109928-109928
Open Access | Times Cited: 67
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Meng Yuan, Deli Huang, Chang‐Chun D. Lee, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 56
Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues
Fan Yang, Sandra C. A. Nielsen, Ramona A. Hoh, et al.
Science (2021) Vol. 372, Iss. 6543, pp. 738-741
Open Access | Times Cited: 55
Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
Norma A. Valdez‐Cruz, Enrique García‐Hernández, Clara Espitia, et al.
Microbial Cell Factories (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 48
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation and antigenicity
S. Gobeil, Katarzyna Janowska, Shana McDowell, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 46
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
David R. Martinez, Alexandra Schäfer, Sarah R. Leist, et al.
Cell Reports (2021) Vol. 36, Iss. 4, pp. 109450-109450
Open Access | Times Cited: 45
A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice
David R. Martinez, Alexandra Schaefer, S. Gobeil, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 43
Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer strategy in management
Nobunao Ikewaki, Gene Kurosawa, Gary Levy, et al.
Vaccine (2023) Vol. 41, Iss. 15, pp. 2427-2429
Open Access | Times Cited: 16
Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview
Rukmankesh Mehra, Kasper P. Kepp
ACS Infectious Diseases (2021) Vol. 8, Iss. 1, pp. 29-58
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top